FDA hands Capri­cor a CRL for its Duchenne cell ther­a­py  

Capri­cor Ther­a­peu­tics said on Fri­day it re­ceived a Com­plete Re­sponse Let­ter from the FDA for its lead cell ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy (DMD), cit­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER